Zobrazeno 1 - 10
of 488
pro vyhledávání: '"Kiyohiko Hatake"'
Autor:
Masahiro Yokoyama, Yoshiharu Kusano, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Tomoyuki Nukada, Kiyohiko Hatake, Yasuhito Terui
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma re
Externí odkaz:
https://doaj.org/article/c104cb09f17a477da0b8915bcb699586
Autor:
Ippei Fukada, Kazuhiro Araki, Kokoro Kobayashi, Tomoko Shibayama, Shunji Takahashi, Rie Horii, Futoshi Akiyama, Takuji Iwase, Shinji Ohno, Kiyohiko Hatake, Yasuo Hozumi, Naohiro Sata, Yoshinori Ito
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0162616 (2016)
BACKGROUND:Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definit
Externí odkaz:
https://doaj.org/article/4b2a2ec49eb64d5c81c0693f028ac2c7
Autor:
Hideaki Nitta, Yasuhito Terui, Masahiro Yokoyama, Yuko Mishima, Noriko Nishimura, Kyoko Ueda, Yoshiharu Kusano, Naoko Tsuyama, Kengo Takeuchi, Yoshinobu Kanda, Kiyohiko Hatake
Publikováno v:
Haematologica, Vol 100, Iss 1 (2015)
Recently, elevated peripheral blood monocyte counts at diagnosis have been shown to be an independent marker associated with poor prognosis in patients with both non-Hodgkin and Hodgkin lymphoma. In this study, we retrospectively analyzed the data fr
Externí odkaz:
https://doaj.org/article/b3efb101a09742fa862b77ba74e90397
Autor:
Satoshi Takagi, Shigeo Sato, Tomoko Oh-hara, Miho Takami, Sumie Koike, Yuji Mishima, Kiyohiko Hatake, Naoya Fujita
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e73609 (2013)
The platelet aggregation-inducing factor Aggrus, also known as podoplanin, is frequently upregulated in several types of tumors and enhances hematogenous metastasis by interacting with and activating the platelet receptor CLEC-2. Thus, Aggrus-CLEC-2
Externí odkaz:
https://doaj.org/article/371badaf6d0b449ca1ff7fa393a4d7f9
Publikováno v:
Mediators of Inflammation, Vol 2010 (2010)
Mucosal damage is a common side effect of many cancer treatments, especially radiotherapy and intensive chemotherapy, which often induce bone marrow (BM) suppression. We observed that acetic acid- (AA-) induced mucosal damage in the colon of mice was
Externí odkaz:
https://doaj.org/article/c7af8fd632114a6dae5b9e9c6781a23d
Autor:
Noriko Fukuhara, Dai Maruyama, Kiyohiko Hatake, Hirokazu Nagai, Shinichi Makita, Kenjiro Kamezaki, Toshiki Uchida, Shigeru Kusumoto, Junya Kuroda, Chisako Iriyama, Masamitsu Yanada, Norifumi Tsukamoto, Youko Suehiro, Hironobu Minami, Jose Garcia-Vargas, Barrett H. Childs, Masanobu Yasuda, Shigeo Masuda, Toshiaki Tsujino, Yui Terao, Kensei Tobinai
Publikováno v:
International Journal of Hematology. 117:100-109
The safety, efficacy, and pharmacokinetics of copanlisib were evaluated in this phase Ib/II study in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). The primary endpoint was safety at the recommended dose; efficacy end
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
Purpose: To evaluate the safety, preliminary efficacy, and pharmacokinetics of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in combination with the immunochemotherapeutic regimen, rituximab, cyclophosphamide, vincristine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35943ae76940aafc27c3ef3e767c0255
https://doi.org/10.1158/1078-0432.c.6524378.v1
https://doi.org/10.1158/1078-0432.c.6524378.v1
Autor:
Kiyohiko Hatake, Kiyotsugu Kojima, Masahiro Yokoyama, Hiroaki Asai, Daisuke Ennishi, Suzuka Asai, Kengo Takeuchi, Yasuhito Terui, Yuko Matsumoto-Mishima, Natsuhiko Sugimura, Yuji Mishima
Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b60b8d491aa301bdf35dec127985fb
https://doi.org/10.1158/1078-0432.22439626.v1
https://doi.org/10.1158/1078-0432.22439626.v1
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
Table S1. Dose Escalation of C (3 levels) or InO (2 levels) and Treatment Schedule Used to Determine the MTD Based on a Standard 3+3 Design; Table S2. AEs Leading to Permanent Discontinuation or Modification of the MTD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292287707d94f0bbbf44fee9335e0ac0
https://doi.org/10.1158/1078-0432.22460018
https://doi.org/10.1158/1078-0432.22460018
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
SUPPLEMENTARY METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680c53c2e6aad14300222af7086c39cd
https://doi.org/10.1158/1078-0432.22460021
https://doi.org/10.1158/1078-0432.22460021